Semi-Chronologic Updates
Updated Dec 14, 2024
NAS - Cannabis Policy Impacts - 2024
Page 33 - Now that states have been legalizing cannabis, what public health measures should be undertaken to protect public health?
NRC - An Analysis of Marijuana Policy - 1982
Marijuana: A Signal of Misunderstanding - 1972
Chapter V - Marihuana and Social Policy - Olmstead v. USA - Judge Brandeis - 1928 - The makers of our Constitution undertook to secure conditions favorable to the pursuit of happiness. They recognized the significance of man's spiritual nature, of his feelings and his intellect. They knew that only a part of the pain, pleasure and satisfaction of life are to be found in material things. They sought to protect Americans in their beliefs, their thoughts, their emotions and their sensations. They conferred, as against the Government, the right to be let alone-the most comprehensive of rights and the right most valued by civilized men.
FR - Proposed Rule for Two Synthetic Opioids - 17Sep24
Footnote 10: On April 11, 2024, the Department of Justice's Office of Legal Counsel (OLC) issued an opinion, which, among other things, concluded that HHS's two-part test would be sufficient to establish that a drug has a currently accepted medical use.
MM - Testifying Schedule for Designated Participants - Dec 4, 2024
DEA - Hearing Proceedings - Day 1 - Dec 2, 2024
MM - Rescheduling Hearings Begin - Dec 2, 2024
MJBizCon - Rescheduling Hearing Opens - Dec 2, 2024
DEA Marijuana Rescheduling Proceedings - ALJ Orders
MJBiz - DEA selects 25 participants - Oct 31, 2024
The Guardian - Nearly 43,000 People Commented - Jul 27, 2024
Headset - Unprecedented Support for Rescheduling - Jul 23, 2024
MM - Feds to Weight 40,000 Comments - Jul 23, 2024
Pennsylvania Department of Health - Public Comment - Jul 22, 2024
CANNRA - Public Comment - Jul 17, 2024
Governor Green - Response - Jun 17, 2024
Governor Green Notification - Jun 14, 2024
DEA-1362 - Public Comment - Otto - Jun 14, 2024
Federal Register - NPRM - May 21, 2024
89 FR 44597-44622 - May 21, 2024
DEA - NPRM - Marijuana Rescheduling - May 16, 2024
“If marijuana is transferred into schedule III, the manufacture, distribution, dispensing, and possession of marijuana would remain subject to the applicable criminal prohibitions of the CSA. Any drugs containing a substance within the CSA’s definition of “marijuana” would also remain subject to the applicable prohibitions in the Federal Food, Drug, and Cosmetic Act (“FDCA”).”
AP - US poised to ease restrictions - Apr 30, 2024
“Schedule III drugs are still controlled substances and subject to rules and regulations, and people who traffic in them without permission could still face federal criminal prosecution.”
Forbes - DEA agrees to reclassify - Apr 30, 2024
MM - DEA agrees to reschedule - Apr 30, 2024
NORML - DEA accepts recommendation - Apr 30, 2024
21 USC 822 - Persons required to register
21 CFR 1301.11 - Persons required to register
Chronic Pain (21%) x Hawaii Adult Population (1,062,002) = 223,020 Potential Patients
“The attorney general is the chief legal officer under the Constitution, and what that means is that we advise all three branches of government: executive, judicial and the legislature as well.” Article word count = 3753, Word search = Federal, Hits = 0.
USA v. Alston - Opening Brief - Mar 7, 2024
“While “[t]he Second Amendment … ‘elevates above all other interests the right of law-abiding, responsible citizens to use arms’ for self-defense,” unlawful users of controlled substances are not responsible citizens and are not guaranteed unfettered Second Amendment rights.”
HOUSE BILLS
HB 1596 HD1 - Decriminalize One Ounce - Never Heard by FIN
HB 1952 HD1 - Dispensary Wholesaling - Never Heard by FIN
HB 2443 HD2 SD1 - Patient Cultivation and Caregiving - FIN release denied
HB 2445 - Post-market Testing - Deferred by JHA/AGR
HB 2600 - Adult Use - Never Heard by JHA/AGR
SENATE BILLS
SB 2461 SD2 HD1 - Dispensary Wholesaling - Act 172
SB 2487 SD1 HD1 - Decriminalize One Ounce - Failed final Senate reading
SB 2619 - Medical Cannabis Farming - Never Heard by HHS/CPN
SB 3132 SD1 - Patient Cultivation and Caregiving - Never Heard by JDC/WAM
SB 3134 - Post-market Testing - Never Heard by HHS/CPN
SB 3278 - Patient Protections - Never Heard by HHS/CPN
SB 3335 SD2 HD2 - Adult Use - Never Heard by FIN
Senate Majority Legislative Priorities for 2024
Senate President Kouchi - Constitutional Duty - Jan 17, 2024
MM - Marijuana Legalization Top Senate Priority - Jan 16, 2024
MM - Congressional Researches Detail Limitations of Rescheduling - Jan 16, 2024
CSR - The Legal Consequences of Rescheduling Marijuana - Jan 16, 2023
Forbes - FDA Review - Jan 16, 2024
Pennington - Freeing the Medical-Cannabis Industry - Jan 16, 2024
AG - Hawaii Cannabis Bill - Press Release - Jan 5, 2024
AG - Hawaii Cannabis Bill - Final Draft Report - Jan 5, 2024
AG - Hawaii Cannabis Bill - Final Draft - Jan 5, 2024
AG - Hawaii Cannabis Bill - Final Draft TOC - Jan 5, 2024
AG - Hawaii Cannabis Bill - Working Draft - Nov 9, 2023
Homeland Security Investigations (HSI)
USSC - Mandatory Minimum Penalties for Drug Offenses
DOH Letter Sent to Patients with a Grow Site Registered at CW - October 26, 2023
KITV4 - Federal Agents Seize 1,100 Plants - October 26, 2023
KITV4 - Marijuana Farm Plans to Reopen - October 30, 2023
KITV4 - Push to License Medical Cannabis Farms - November 2, 2023
Senator Awa - Hawaii Medical Use of Cannabis Act of 2024 - Draft
31 CFR 1020.320 - Reports By Banks Of Suspicious Transactions
ASA - Cannabis Scheduling Blog - August 31, 2023
Governor Polis - Rescheduling Letter to President Biden - September 5, 2023
ASA - Cannabis in Schedule III ? - September 7, 2023
Matt Zorn - The Dirtiest Little Secrets About Rescheduling - September 7, 2023
Chris Roberts - DEA Now Key To Rescheduling - September 12, 2023
There’s currently no example of a Schedule 3 controlled substance that hasn’t been approved by the FDA being sold in stores without the DEA’s blessing.
CRS - HHS Rescheduling Recommendation - September 13, 2023
21 CFR 1301 - Registration of Manufacturers of Controlled Substances
SEC. 301. DOCTOR-PATIENT RELATIONSHIP.
It shall not be a violation of the Controlled Substances Act (21 U.S.C. 801 et seq.) for a State-licensed physician to discuss—
(1) the currently known potential harms and benefits of marijuana derivatives, including cannabidiol, as a treatment with the legal guardian of the patient of the physician if the patient is a child; or
(2) the currently known potential harms and benefits of marijuana and marijuana derivatives, including cannabidiol, as a treatment with the patient or the legal guardian of the patient of the physician if the patient is a legal adult.
HAH has improved public and governmental response to the financial and regulatory challenges faced by its members by articulating those challenges, and developing solutions that meet the needs of its members and the people they serve.
Chapter 11-850 - HAR - Interim Dispensary Rules - August 7, 2023
Chapter 11-850 - HAR - Interim Dispensary Rules - November 17, 2022
Chapter 11-850 - HAR - Interim Dispensary Rules - April 29, 2022
Chapter 11-850 - HAR - Interim Dispensary Rules - February 24, 2022
Chapter 11-850 - HAR - Interim Dispensary Rules - December 14, 2015
Health and Temperance, page 152: When we practice the principles of healthful living, we will not feel the need for stimulants. Nature’s law forbids our use of intoxicants and narcotics of any kind. From the early days of this movement abstinence from the use of liquor and tobacco has been a condition of membership. (See pp. 50, 52, 67-68, 100, 175-176.)
Baptismal Vow and Commitment, page 52: 10. Do you believe that your body is the temple of the Holy Spirit; and will you honor God by caring for it, avoiding the use of that which is harmful, and abstaining from all unclean foods; from the use, manufacture, or sale of alcoholic beverages; from the use, manufacture, or sale of tobacco in any of its forms for human consumption; and from the misuse of or trafficking in narcotics or other drugs?
Reasons for Discipline, page 68: 14. The use or manufacture of illicit drugs or the use, misuse, or sale of narcotics or drugs without appropriate medical cause and license.
Health Ministries, page 100: In addition to ministering to those who are ill, this responsibility extends to the prevention of disease through effective health education and leadership in promoting optimum health, free of tobacco, alcohol, other drugs, and unclean foods.
IOWASKA CHURCH OF HEALING v. USA - March 31, 2023
Page 11 - the CSA authorizes the Attorney General to create exemptions from the prohibitions on handling controlled substances, see 21 U.S.C. § 822(d), and individuals seeking a CSA exemption must file a written request to the DEA Administrator to obtain that exemption, as plaintiff has done here. See 21 C.F.R. § 1307.03
INCB Concerns Over Legalization - March 9, 2023
In the report, INCB clarifies that the cultivation and use of cannabis for medical purposes is permitted, as long as certain conditions of the conventions are met surrounding licensing, national controls and provision of estimates of medical requirements to INCB. The report notes that in some States, “medical cannabis programmes” are operating without these controls and without meeting WHO standards related to manufacturing and prescribing.
Blake Oshiro, a senior adviser to Green, said the governor remained supportive of allowing adults to use cannabis but he wants to make sure that any legislation protects public safety and consumers.
HOUSE BILLS
HB237 - Relating to Cannabis - Adult Use - Kapela (SB375)
HB238 - Relating to Medical Cannabis - Employment - Kapela (SB377)
HB957 - Relating to Medical Cannabis - Ryan’s Law - Hussey-Burdick (SB673)
HB1216 - Relating to Cannabis - Adult Use - Belatti
HB1217 - Relating to Medical Cannabis - Cultivation Limits - Belatti (SB1570)
HLT - Public Hearing - Feb 4 - 27:17
SENATE BILLS
SB375 - Relating to Cannabis - Adult Use - Lee (HB237)
SB465 - Relating to Medical Cannabis - Interisland Transportation - San Buenaventura
SB669 - Relating to Cannabis - Adult Use - San Buenaventura
SB673 - Relating to Medical Cannabis - Ryan’s Law - San Buenaventura (HB957)
SB962 - Relating to Medical Cannabis - Fees Rules Products - Keohokalole (HB1218)
SB1104 - Relating to Cannabis for Medical Use - Cuttings - Keith-Agaran (HB1219)
SB1570 - Relating to Medical Cannabis - Cultivation Limits - Keohokalole (HB1217)
White House Marijuana Announcement - October 6, 2022
MM - Scheduling Review Will Move Quickly - October 7, 2022
Biden’s Scheduling Directive Part II - Shane Pennington - October 13, 2022
MM - Scheduling Review Update - December 2, 2022
21 USC 811 - Authority and criteria for classification of substances
21 USC 801 - Congressional findings and declarations
HHS - Marijuana Scheduling Review - May 20, 2015
DEA - Denial of Petition to Initiate Rescheduling Proceedings - August 12, 2016
AG says DOJ will address Marijuana issues in the days ahead - June 16, 2022
“Marijuana remains popular and in abundance in Hawaii, and with the development of legalized medical marijuana dispensaries and efforts for full legalization, it is anticipated that Hawaii will mirror the ramifications of legalized marijuana as in the state of Colorado: black market marijuana production and distribution will flourish in Hawaii, children will be using marijuana at a younger age and illicit outdoor marijuana cultivation will prevail in the remote areas of the Hawaiian Islands.”
Meeting 1 - Notice and Agenda - April 25, 2022
Meeting 1 - Written Testimony - Dr. Otto - April 25, 2022
OIP - Open Meeting Sunshine Rules
Meeting 1 - Zoom Recording - April 25, 2022
Meeting 2 - Notice and Agenda - May 23, 2022
Meeting 2 - Rescheduled Notice and Agenda - May 31, 2022
Meeting 2 - Zoom Recording - May 31, 2022
DUTF2 - Dr. Otto’s Public Testimony on Agenda Item III - May 31, 2022
Meeting 3 - Zoom Recording - June 27, 2022
DUTF4 - Dr. Otto’s Public Testimony on Agenda Item II - August 2, 2022
DUTF4 - Dr. Otto’s Public Testimony on Agenda Item III - August 2, 2022
DUTF5 - Patient and Provider Rapid Survey Results - August 22, 2022
DUTF5 - Agenda Item II - Dr. Otto’s Public Testimony - August 29, 2022
DUTF5 - Agenda Item III - Dr. Otto’s Public Testimony - August 29, 2022
“The Task Force concludes that neither a federal crackdown nor a hands-off approach is advisable. In the absence of cannabis rescheduling, or its legalization at the federal level, the Task Force recommends that Congress and the Administration develop a state waiver process or contractual framework. Without it, states and the industry will continue to exist under an illusion of sovereignty where circumstances can change at any moment. A balanced and thoughtful accommodation from the federal government would provide confidence to states, stabilize the market, and help address many of the myriad safety and health problems.”
“The bill, sponsored by Democratic Rep. Jerry Nadler of New York, will prevent federal agencies from denying federal workers security clearances for cannabis use, and will allow the Veterans' Administration to recommend medical marijuana to veterans living with posttraumatic stress disorder, plus gains revenue by authorizing a sales tax on marijuana sales.”
The federal Bureau of Labor Statistics shall maintain a national public database of all business owners and individuals who are employed in the cannabis industry.
HACDACS 2021 Report to the Legislature - December 31, 2021
Page 16: "HACDACS recommends pursuing all available options for protecting Hawaii’s medical cannabis patients from legal repercussions related to the federal prohibition and current Federal scheduling of Cannabis as a schedule 1 drug. An advisory group consisting of representatives from involved state and local agencies, the medical community, the medical cannabis industry and community groups may provide added resources and expertise to help solve this difficult problem."
“The medical community agrees that we need more research to learn about marijuana’s potential health benefits, but our federal laws today are standing in the way of us finding those answers,” said Senator Schatz. “We are now one step closer to removing excessive barriers that make it difficult for researchers to study the effectiveness and safety of marijuana, and hopefully, give patients more treatment options.”
Senator English Sentenced to 40 Months - July 5, 2022
KHON2 - English and Cullen Plead Guilty
KITV - Thirteen Lawmakers Return Campaign Contributions - February 11, 2022
KITV - Wire Fraud Charges Filed - February 8, 2022
USA vs. English - District Attorney Connors - February 8, 2022
USA vs. Cullen - District Attorney Connors - February 8, 2022
SB2380 - Relating to Environmental Protection - January 17, 2020
HB1170 - Relating to Environmental Protection - January 24, 2019
2022 House Bills
HB2260 - Expanding Dispensaries - January 25, 2022
HB2260 - Notice of Hearing - HHH - February 8, 2022
HB2260 - HHH - Public Testimony from Dr. Otto - February 8, 2022
HB2260 - HHH - Question from Representative Ward - February 8, 2022
HB2260 - HHH - Decision Making - February 8, 2022
HB2260 HD1 - HHH Amendments - February 10, 2022
HB2260 HD1 - Notice of Hearing - CPC - February 15, 2022
HB2260 HD1 - Written Testimony from Dr. Otto - February 15, 2022
HB2260 HD1 - Notice of Hearing - FIN - March 1, 2022
HB2260 HD1 - Written Testimony from Dr. Otto - March 1, 2022
HB2260 HD1 - Notice of Hearing - HTH-CPN - March 15, 2022, 9:30 AM
HB2260 HD1 - HTH-CPN - Public Testimony - March 15, 2022
HB2260 HD1 - HTH-CPN - Public Testimony from Dr. Otto - March 15, 2022
2022 Senate Bills
“Until rigorous evidence about the benefits and risks of medical cannabis is available, policymakers must ensure that transparency and safety are prioritized to support patients and clinicians alike.”
Based upon a telephone conversation with the Elder of the Bible Questions Desk at the New York Headquarters on November 9, 2021, the medical use of cannabis that is authorized by a physician and being used under medical supervision does not constitute a scriptural violation and is considered a “personal choice”. The Elder recommended that members making this personal choice let their local Elder know so there is no misunderstanding within the community, but only if the member is comfortable sharing this confidential medical information.
State Attorney General Clare Connors said in oral arguments before the court last year that the state constitution mandated only that a bill have a broad enough title to encompass the changed content and that the bill be in its final form when it goes up for its last vote. She argued the Legislature needed flexibility to be able to substitute bill content to allow it to respond to unforeseen emergencies, like when it passed measures to respond to flooding on Kauai in 2019 and when it passed legislation to address the coronavirus pandemic in 2020.
Today is an important day for the State of California.
Twenty-five years ago (November 5, 1996) California enacted Proposition 215, also known as the Compassionate Use Act, which created the first state authorization for the medical use of cannabis.
We don’t know why California didn't work with the DEA to prevent a conflict with the federal regulation of marijuana. Maybe because Prop 215 was enacted by voter initiative they figured it wasn’t worth the effort, or maybe they didn't realize that a solution exists.
But the situation is very different in Hawaii, where our Medical Use of Cannabis Act was enacted via the legislative process, and we have a solution for the ongoing federal conflict that was unanimously adopted by both chambers of the Legislature last Session.
Now we just need to follow through on HCR132, to protect our patients and prevent our state from falling prey to the false promises of recreational legalization.
On Capitol Hill, the whispers of federal marijuana reform and legalization have grown into a clamor. But because of a lack of consensus among lawmakers and industry members, change is not on the immediate horizon, Walsh said.
"I'm still doubtful that we're going to see any significant federal reform next year ... including in banking," Walsh told CNN Business, referencing longstanding efforts to change federal law to allow state-legal cannabis businesses (and those that serve them) access to traditional banking services.
"I agree that it's an uphill slog to see federal legalization, but what we're putting on the table is inevitability," Steven Hawkins, CEO of the US Cannabis Council and executive director of the Marijuana Policy Project, said during a MJBizCon panel on federal legalization. "When you get to the point when half of the country has legalized for adult-use, we have now set a stage for inevitability. And that begins to change the tone and tenor in Washington."
REQUESTING THE DEPARTMENT OF HEALTH TO APPLY TO THE DRUG ENFORCEMENT ADMINISTRATION'S OFFICE OF DIVERSION CONTROL FOR AN EXCEPTION UNDER TITLE 21 CODE OF FEDERAL REGULATIONS SECTION 1307.03, AND REQUEST FORMAL WRITTEN ACKNOWLEDGMENT THAT THE LISTING OF MARIHUANA, MARIHUANA EXTRACT, AND TETRAHYDROCANNABINOLS AS CONTROLLED SUBSTANCES IN FEDERAL SCHEDULE I DOES NOT APPLY TO THE PROTECTED ACTIVITIES IN HAWAII REVISED STATUTES.
HCR132 HD1 SD1 - Certified Copy - May 4, 2021
Letter to Governor Ige - Update on Federal Exemption - May 15, 2021
“The legislature further finds that allowing the medical use of marijuana could promote Hawaii as being an international center for medical treatment and research.”
Sec. 96. FEDERAL SCHEDULE I EXEMPTION APPLICATION FOR MEDICAL USE OF CANNABIS (Page 252).
By September 1, 2021, the commissioner of health shall apply to the Drug Enforcement Administration's Office of Diversion Control for an exception under Code of Federal Regulations, title 21, section 1307.03, and request formal written acknowledgment that the listing of marijuana, marijuana extract, and tetrahydrocannabinols as controlled substances in federal Schedule I does not apply to the protected activities in Minnesota Statutes, section 152.32, subdivision 2, pursuant to the medical cannabis program established under Minnesota Statutes, sections 152.22 to 152.37. The application shall include the list of presumptions in Minnesota Statutes, section 152.32, subdivision 1.
Dr. Chanda Macias: “The states have really taken a proactive approach with protecting patients, which I adore. Now, federally, we need to lead the way. But also with that, I think about banking issues. What a lot of people don't know is that we can't use traditional banks in this space because it's still federally illegal.”
HCR132 - Federal Exemption Resolution - Offered on March 12, 2021
HCR132 - Written Testimony from Dr. Otto - March 23, 2021
HCR132 - All Written Testimony - HHH - March 23, 2021
HCR132 - Public Testimony - HHH - March 23, 2021
HCR132 - Decision Making - HHH - March 23, 2021
HCR132 HD1 - Public Testimony - JHA - March 29, 2021
HCR132 HD1 - Decision Making - JHA - March 29, 2021
HCR132 HD1 - Written Testimony - Dr. Otto - April 9, 2021
HCR132 HD1 - Public Hearing and Decision Making - HTH - April 9, 2021
HCR132 HD1 - ALL WRITTEN TESTIMONY - HTH - April 9, 2021
HCR132 HD1 SD1 - Amended by HTH - April 13, 2021
HCR132 HD1 SD1 - Written Testimony from Dr. Otto - JDC - April 16, 2021
HCR132 HD1 SD1 - ALL TESTIMONY - April 16, 2021
Hawaii State Oath of Office
Article XVI, section 4, of the Hawaii constitution
All eligible public officers, before entering upon the duties of their respective offices, shall take and subscribe to the following oath or affirmation: "I do solemnly swear (or affirm) that I will support and defend the Constitution of the United States, and the Constitution of the State of Hawaii, and that I will faithfully discharge my duties as ____________ to the best of my ability."
SB1139 - Registration Fee Increase Bill - Introduced January 27, 2021
SB1139 - Written Testimony from Dr. Otto - February 3, 2021
SB1139 - All Written Testimony - February 3, 2021
SB1139 - Public Testimony by Dr. Otto - February 3, 2021
Letter to Senator Dela Cruz - Concerns about SB1139 - February 5, 2021
SB1139 SD1 - Written Testimony from Dr. Otto - February 26, 2021
SB1139 SD2 - Written Testimony from Dr. Otto - March 16, 2021
SB1139 SD2 - Before HHH - Dr. Otto’s Public Testimony - March 16, 2021
SB1024 - Cannabinoid Medicine Program Bill - Introduced January 27, 2021
Senator Kim - Hearing Request for SB1024 - January 29, 2021
Senator Keohokalole - Hearing Request for SB1024 - January 29, 2021
SB1024 - Hearing Notice - Thursday, February 11, 2021 at 3:05 PM
SB1024 - Written Testimony from Dr. Otto - February 11, 2021
SB1024 - Public Testimony by Dr. Otto - February 11, 2021
SB1024 - Decision Making - February 16, 2021
Senator Dela Cruz - Hearing Request for SB1024 - February 16, 2021
SB1333 - FDA-Approved Cannabidiol Bill - Introduced January 27, 2021
SB1333-SD1 - FDA-Approved Cannabidiol Bill Update
SB1333-SD1 - Hearing Notice - JDC - Wed - February 17, 2021 at 1000 AM
Senator Rhoads - Request for Proposed SD2 on SB1333 SD1 - February 15, 2021
SB1333 SD1 - Written Testimony by Dr. Otto - February 17, 2021
HB477 - Stop Patient Cultivation Bill - Introduced January 25, 2021
HB477 HD1 - Amended by HHH on February 5, 2021
HB477 HD1 - Written Testimony by Dr. Otto to CPC - February 16, 2021
HB477 HD2 - Amended by CPC on February 16, 2021
HB477 HD2 - Written Testimony by Dr. Otto to FIN - February 25, 2021
HB477 HD2 - Public Testimony by Dr. Otto before FIN - February 25, 2021
HB477 HD2 - Public Testimony by HICIA to FIN - February 25, 2021
HB477 HD2 - Decision Making by FIN - February 25, 2021
HB477 HD2 - Written Testimony by Dr. Otto - March 19, 2021
HB477 HD2 - Public Testimony by Dr. Otto - March 19, 2021
HB477 HD2 - Decision making by HTH and CPC - March 19, 2021
HB477 HD2 SD1 - Written Testimony from Dr. Otto - April 6, 2021
HB477 HD2 SD1 - Decision Making - JDC - WAM - April 6, 2021
HB477 HD2 SD2 - Conference Comments from Dr. Otto - April 16, 2021
HB477 HD2 SD2 - Conference Committee Meeting - April 21, 2021
SB669 - Federal Exemption Bill - Introduced January 22, 2021
Senator Dela Cruz - Thank You for SB669 - January 23, 2021
Senator Dela Cruz - DOE Position on Federal Exemption - January 31, 2021
Senator Keohokalole - Hearing Request for SB669 - February 1, 2021
Senator Nishihara - Hearing Request for SB669 - February 1, 2021
Senator Nishihara - Hearing for Federal Exemption Bills - February 4, 2021
SB241 - Interisland Transport Bill - Introduced January 22, 2021
SB241 - Written Testimony by Dr. Otto - February 3, 2021
SB241 - Complete Testimony - February 3, 2021
SB241 - Public Testimony by Dr. Otto - February 3, 2021
SB241 - Decision Making - HTH Chair Comments - February 3, 2021
SB241 - Letter to HTH Chair on Decision Making - February 4, 2021
Senator Rhoads - Hearing Request for SB241 - February 4, 2021
SB147 - Federal Exemption Bill - Introduced January 21, 2021
Senator San Buenaventura - Thank You for SB147 - January 23, 2021
Senator Keohokalole - Hearing Request for SB147 - January 23, 2021
Senator Nishihara - Hearing Request for SB147 - January 23, 2021
Senator San Buenaventura - DOE Position on Federal Exemption - January 31, 2021
Senator Nishihara - Hearing for Federal Exemption Bills - February 4, 2021
REQUEST FOR INFORMATIONAL BRIEFING
Council on Developmental Disabilities - Executive Board Meeting - December 14, 2020
FEDERAL EXEMPTION PROPOSAL FOR 2021 SESSION
SENATE COMMITTEE ON HEALTH HAS BEEN RESURRECTED !
Civil Beat Article on Recreational Cannabis - November 11, 2020
“Sen. Jarrett Keohokalole, who was recently named chairman of the Senate Health Committee, said he does plan to hold a hearing on a legalization bill in the legislative session that begins in January.”
NEW DOH DIRECTOR - LIBBY CHAR, MD
First Press Conference as Director of DOH on September 16, 2020
"We need to make sure that we're paying attention to our health beyond COVID.”
RESURRECT THE SENATE COMMITTEE ON HEALTH
2020 Legislative Session
HB2097 HD2 SD2 - Comments to Governor Ige - 12Jul20
HB2097 HD2 SD1 - Relating to Medical Cannabis (Remediation, Edibles, Education) - Testimony - 30Jun20
HB2097 HD1 - Written Testimony - Peter Oshiro - February 12, 2020
HB2097 SD1 - Written Testimony - Department of Health - June 30, 2020
Response to Attorney General guidance on SB2462 - 09Feb20
Attorney General guidance on SB2462 - 05Feb20
SB2462 - Relating to Controlled Substances - CPH on 31Jan20 - Testimony
Federal Exemption Resolution Draft - Senate Version
Federal Exemption Resolution Draft - House Version
Federal Exemption Bill Draft - Senate Version - Updated 21Dec19
Federal Exemption Bill Draft - House Version - Updated 21Dec19
329 Veteran Standown - Dr. Otto’s Presentation - September 14, 2019
2019 LEGISLATIVE SESSION
HCR89 - Requesting Congressional Action - PSM on 04/16/2019 - Testimony
GM543 - Relating to Nominee Espinda - PSM on 04/04/2019 - Testimony
HB673 HD2 SD1 - Relating to Medical Cannabis - JDC/WAM on 04/03/2019 - Testimony
SB1263 SD1 - Relating to the UCSA - JUD on 03/25/2019 - Testimony
HCR89 - Requesting Congressional Action - JUD on 03/22/2019 - Testimony
HB673 HD2 - Relating to Medical Cannabis - CPH on 03/21/2019 - Testimony
SB1263 SD1 - Relating to the UCSA - HLT on 03/21/2019 - Testimony
HB1383 HD2 - Relating to Marijuana - JDC on 03/19/2019 - Testimony
SB1353 SD3 HD1 - Relating to Industrial Hemp - JUD on 03/18/2019 - Testimony
HB290 HD1 - Relating to the UCSA - CPH on 03/15/2019 - Testimony
GM541 - Relating to Nominee Anderson - CPH on 2/25/2019 - Testimony
HB673 HD2 - Relating to Medical Cannabis - FIN on 02/21/2019 - Testimony
SB1263 - Relating to the UCSA - CPH on 02/20/19 - Testimony
HB131 HD2 - Relating to Hemp - FIN on 2/20/2019 - Testimony
SB541 - Relating to Medical Cannabis Products - CPH on 02/20/2019 - Testimony
SB1353 SD1 - Relating to Industrial Hemp - WAM on 02/19/19 - Testimony
HB673 HD1 - Relating to Medical Cannabis - JUD on 02/14/19 - Testimony
SB1266 - Relating to the UCSA - CPH on 02/13/19 - Testimony
HB131 HD1 - Relating to Hemp - JUD on 02/12/2019 - Testimony
HB290 - Relating to the UCSA - JUD on 02/07/2019 - Testimony
SB527 - Relating to Cannabis for Medical Use - CPH on 02/06/19 - Testimony
HB131 - Relating to Hemp - AGR on 02/06/2019 - Testimony
HB673 - Relating to Medical Cannabis - HLT on 02/05/19 - Testimony
SB1335 - Relating to Hemp - AEN on 02/04/19 - Testimony
SB686 - Relating to Marijuana - JDC on 01/31/19 - Testimony
FDA Call for Comments on CBD - Testimony - May 28, 2019
DOJ Marijuana Summit - March 28, 2019 - Agenda - Dr. Otto’s Presentation
FDA Request for Comments - Impact of State Medical Use - April 23, 2018
Testimony for HB2572 - Relating to the Medical Use of Cannabis - February 7, 2018
APPEARANCES
ONLINE ARTICLES
NEWSPAPER MENTIONS
LETTERS TO THE EDITOR
PRESENTATIONS
John Burns School of Medicine - Medical Cannabis: What's the Evidence ? - CME event - November 4, 2017
ARTICLES IN PRINT
Concerns about Hemp-CBD - 2016